Navigation Links
Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East
Date:11/20/2009

HAIFA, Israel, November 20 /PRNewswire-FirstCall/ -- Cardio Vascular Medical Device Corp. (CVSL.OB), http://www.CVSLMEDICAL.COM, a leading developer of advanced cardiovascular surgery technology, today announced that the company's Board of Directors has decided to initiate patent applications in Europe, Canada and the Far East for its proprietary next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures.

Cardio Vascular Medical Device already holds a US patent for the innovative guidewire. The company has elected to apply for the additional patents in order to penetrate a worldwide commercial marketplace for the life-saving angioplasty procedure.

Angioplasty is a common procedure that is performed to widen narrowed or obstructed blood vessels. The procedure is often performed in place of, or before a more invasive and potentially life-threatening bypass surgery is needed. Angioplasty that is performed before an artery is fully-blocked can prevent the onset of heart attacks.

More than seven million angioplasties are performed worldwide each year. The potential addressable market for angioplasty equipment exceeds $500 million.

According to the World Health Organization, some 7.2 million men and women die as a result of cardiac heart disease. Heart disease is the leading cause of death for both women and men in the United States.

"Filing these additional patent applications is the first stage in aiding cardiologists in the process of saving lives across the globe," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp.

"The ability to steer our guidewire during angioplasty procedures using our patented flexi-tip enables more difficult procedures to be completed with greater ease, and speeds overall procedure time," Gonen added. "Due to these significant advantages, Cardio Vascular Medical Device's guidewire has the opportunity to become the guidewire of choice for surgeons throughout the world."

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated in the forward-looking statements. Cardio Vascular Medical Device Corp. public filings may be viewed at www.sec.gov.

    Contact:

    Alex Traiman
    Media Relations
    +1-646-863-9729

    Asher Zwebner
    +972-54-464-6363
    asher@fxmng.com


SOURCE Cardio Vascular Medicine Device Corp.


'/>"/>
SOURCE Cardio Vascular Medicine Device Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
3. Pot bellies linked to early signs of cardiovascular disease
4. Air pollution linked to cardiovascular risk indices in healthy young adults
5. Environmental stress probed in cardiovascular disease, diabetes
6. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
7. Cardiome to Present at Bear Stearns Conference
8. SCAI and ACC announce new interventional cardiology meeting
9. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
10. Cardiome to Present at ThinkEquity Conference
11. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today a ... the Northeast U.S. , GlycoMark is the only clinically available blood test ... a clinically proven one- to two-week measure of hyperglycemic excursions, often related to ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... could substantially improve drug safety and minimize the cost of development. In this ... channel inhibition using cell lines and for cardiac toxicity using induced pluripotent stem ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at Moffitt Cancer ... CentrePoint Data Hub in a sample of participants enrolled in an ongoing ... sleep monitoring solutions for the global scientific community. The company’s new CentrePoint Data ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... NuevaCare, a ... as diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades ... persons to bookmark and read organized content on topics such as home care (generally) ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE ... Bloom Burton & Co. Healthcare Investor Conference 2017 at the Sheraton ... Edward Wright , Chief Executive Officer of the Company is scheduled ... CFO, Richard Bear and the Chairman of the Board, ... ...
(Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
Breaking Medicine Technology: